Toll Free: 1-888-928-9744

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 48 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Review, H1 2016', provides an overview of the Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polyarticular Juvenile Idiopathic Arthritis (PJIA) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polyarticular Juvenile Idiopathic Arthritis (PJIA)
- The report reviews pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Polyarticular Juvenile Idiopathic Arthritis (PJIA) therapeutics and enlists all their major and minor projects
- The report assesses Polyarticular Juvenile Idiopathic Arthritis (PJIA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Polyarticular Juvenile Idiopathic Arthritis (PJIA)


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Polyarticular Juvenile Idiopathic Arthritis (PJIA) Overview 6 Therapeutics Development 7 Pipeline Products for Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Overview 7 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics under Development by Companies 8 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline Products Glance 9 Late Stage Products 9 Early Stage Products 10 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Products under Development by Companies 11 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Companies Involved in Therapeutics Development 12 Coherus BioSciences, Inc. 12 Epirus Biopharmaceuticals, Inc. 13 Marathon Pharmaceuticals, LLC 14 Mycenax Biotech Inc. 15 Oncobiologics, Inc. 16 Oncodesign SA 17 Panacea Biotec Limited 18 Sandoz International GmbH 19 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 adalimumab biosimilar - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 adalimumab biosimilar - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 deflazacort - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 etanercept biosimilar - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 etanercept biosimilar - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 etanercept biosimilar - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 etanercept biosimilar - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 methotrexate - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 tocilizumab biosimilar - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 tocilizumab biosimilar - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 tocilizumab biosimilar - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Recent Pipeline Updates 42 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Early Stage Development, H1 2016 10 Products under Development by Companies, H1 2016 11 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Coherus BioSciences, Inc., H1 2016 12 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 13 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Marathon Pharmaceuticals, LLC, H1 2016 14 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Mycenax Biotech Inc., H1 2016 15 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncobiologics, Inc., H1 2016 16 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Oncodesign SA, H1 2016 17 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Panacea Biotec Limited, H1 2016 18 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Pipeline by Sandoz International GmbH, H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Polyarticular Juvenile Idiopathic Arthritis (PJIA) Therapeutics - Recent Pipeline Updates, H1 2016 42 Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Dormant Projects, H1 2016 46


List of Figures
Number of Products under Development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 10 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Targets, H1 2016 21 Number of Products by Stage and Targets, H1 2016 21 Number of Products by Mechanism of Actions, H1 2016 23 Number of Products by Stage and Mechanism of Actions, H1 2016 23 Number of Products by Routes of Administration, H1 2016 25 Number of Products by Stage and Routes of Administration, H1 2016 25 Number of Products by Molecule Types, H1 2016 27 Number of Products by Stage and Molecule Types, H1 2016 27

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...

Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected to

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify